Researcher.Life Logo

Neurology and Therapy : Impact Factor & More

eISSN: 2193-6536pISSN: 2193-8253
JournalOpen Access

Key Metrics

CiteScore
5.3
Eigenfactor
0.001 - 0.005
H-Index
29
Impact Factor
< 5
SJR
Q2Neurology
SNIP
1.21
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Neurology and Therapy

Neurology and Therapy Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher SPRINGER LONDON LTD
Language English
Frequency Semi-annual
Article Processing ChargesEUR 5500 | USD 6850 | GBP 4700
Publication Time6
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencySemi-annual
Publication Start Year2012
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 6
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC
OA statementVisit website
View less

Planning to publish in Neurology and Therapy ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Neurology and Therapy

Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.
  • 1 Jun 2026
  • Neurology and therapy
Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.
  • 7 May 2026
  • Neurology and therapy
Real-World Effectiveness and Safety of Ofatumumab: Analysis of BCell Depletion, Comorbidities and Ethnicity in a Spanish Cohort.
  • 6 May 2026
  • Neurology and therapy
Adherence, Persistence, and Safety of Risdiplam in Spinal Muscular Atrophy: A Population-Based Cohort Study.
  • 6 May 2026
  • Neurology and therapy
Predictive Factors for Non-response to First Use of Polyvalent Intravenous Immunoglobulin in Generalised Myasthenia Gravis.
  • 6 May 2026
  • Neurology and therapy
Treatment Preferences for Subcutaneous ImmunoglobulinAmong Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Caregivers, and Physicians: A Discrete Choice Experiment.
  • 6 May 2026
  • Neurology and therapy
Efficacy of Ublituximab in People with Highly Active Relapsing Multiple Sclerosis.
  • 1 Jun 2026
  • Neurology and therapy
Real-World Safety and Effectiveness of 24-Hour Foslevodopa/Foscarbidopa in Parkinson's Disease: ROSSINI Study 6-Month Interim Results.
  • 7 May 2026
  • Neurology and therapy
Real-World Effectiveness and Safety of Ofatumumab: Analysis of BCell Depletion, Comorbidities and Ethnicity in a Spanish Cohort.
  • 6 May 2026
  • Neurology and therapy
Adherence, Persistence, and Safety of Risdiplam in Spinal Muscular Atrophy: A Population-Based Cohort Study.
  • 6 May 2026
  • Neurology and therapy
Predictive Factors for Non-response to First Use of Polyvalent Intravenous Immunoglobulin in Generalised Myasthenia Gravis.
  • 6 May 2026
  • Neurology and therapy
Treatment Preferences for Subcutaneous ImmunoglobulinAmong Patients with Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Caregivers, and Physicians: A Discrete Choice Experiment.
  • 6 May 2026
  • Neurology and therapy

FAQs on Neurology and Therapy